We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

42 hedge funds and large institutions have $1.65M invested in AYTU BioPharma in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,200% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 1

40% more funds holding

Funds holding: 30 → 42 (+12)

0.24% more ownership

Funds ownership: 0.47% → 0.71% (+0.24%)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

34% less capital invested

Capital invested by funds: $2.5M → $1.65M (-$855K)

Holders
42
Holders Change
+12
Holders Change %
+40%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
9
Reduced
10
Closed
1
Calls
$22K
Puts
–
Net Calls
+$22K
Net Calls Change
-$127K

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$569K
2
SM
Sabby Management
Florida
+$479K
3
Renaissance Technologies
Renaissance Technologies
New York
+$262K
4
Walleye Capital
Walleye Capital
New York
+$221K
5
AC
Ayrton Capital
Connecticut
+$172K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$44.8K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$13K
3
Two Sigma Investments
Two Sigma Investments
New York
-$5.49K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$4.01K
5
Morgan Stanley
Morgan Stanley
New York
-$1.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$323K +$262K +34,587 +66%
Alyeska Investment Group
2
Alyeska Investment Group
Illinois
$278K +$569K +75,000 New
SM
3
Sabby Management
Florida
$234K +$479K +63,126 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$180K -$44.8K -5,904 -11%
Walleye Capital
5
Walleye Capital
New York
$108K +$221K +29,125 New
BlackRock
6
BlackRock
New York
$89K -$326 -43 -0.2%
AC
7
Ayrton Capital
Connecticut
$84K +$172K +22,611 New
Millennium Management
8
Millennium Management
New York
$76K +$89.2K +11,752 +134%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$44K -$4.01K -529 -4%
Commonwealth Equity Services
10
Commonwealth Equity Services
Massachusetts
$38K +$37.9K +4,993 +91%
Prudential Financial
11
Prudential Financial
New Jersey
$27K +$39.8K +5,240 +257%
CH
12
CVI Holdings
Delaware
$26K +$53.8K +7,094 New
ACM
13
Allred Capital Management
Texas
$19K +$33.5K +4,418 +531%
State Street
14
State Street
Massachusetts
$18K – – –
WAM
15
Warberg Asset Management
Illinois
$12K +$24.7K +3,250 New
UBS Group
16
UBS Group
Switzerland
$11K +$19.4K +2,554 +832%
TRCT
17
Tower Research Capital (TRC)
New York
$10K +$3.22K +424 +20%
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$10K +$21.4K +2,819 New
Northern Trust
19
Northern Trust
Illinois
$9K -$584 -77 -3%
Group One Trading
20
Group One Trading
Illinois
$8K – – –
IA
21
IFP Advisors
Florida
$8K – – –
Two Sigma Investments
22
Two Sigma Investments
New York
$5K -$5.49K -724 -35%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$5K -$797 -105 -8%
Morgan Stanley
24
Morgan Stanley
New York
$4K -$1.9K -250 -20%
BTI
25
Blue Trust Inc
Georgia
$4K – – –
1
2

AYTU Hedge Fund Activity: Q3 2022 in Review

42 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2022, worth a combined $1.65M — down 34% from $2.5M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AYTU positions and 1 closed out — a net gain of 12 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $569K. The largest seller was Vanguard Group, cutting an estimated $44.8K.

  • 42 institutional investors held AYTU BioPharma (AYTU) as of Q3 2022, up from 30 in Q2 2022.
  • Funds reported $1.65M of AYTU BioPharma stock for Q3 2022, down 34% quarter-over-quarter.
  • 13 funds opened new AYTU BioPharma positions in Q3 2022 and 1 closed out, a net change of +12 holders.
  • The largest AYTU BioPharma buyer in Q3 2022 was Alyeska Investment Group, an estimated $569K added.
  • The largest AYTU BioPharma seller in Q3 2022 was Vanguard Group, an estimated $44.8K sold.

Based on aggregated 13F filings for Q3 2022.